Evidence map›Paper›PMID 37794278›Full record

ArticleInternational journal of behavioral medicine2025

Knowledge of Cannabinoid Content Among People Living with HIV Who Use Cannabis: a Daily Diary Study.

Sophie G Coelho, Sergio Rueda, Cecilia T Costiniuk, Mohammad-Ali Jenabian, Shari Margolese, Enrico Mandarino, Paul A Shuper, Christian S Hendershot, John A Cunningham, Gordon Arbess and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in International journal of behavioral medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Sophie G CoelhoDepartment of Psychology, York University, 277 Behavioural Sciences Building, 4700 Keele St., Toronto, ON, Canada.
Sergio RuedaInstitute for Mental Health Policy Research and Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON, Canada.
Cecilia T CostiniukCIHR Canadian HIV Trials Network, Vancouver, BC, Canada.
Mohammad-Ali JenabianCIHR Canadian HIV Trials Network, Vancouver, BC, Canada.
Shari MargoleseCIHR Canadian HIV Trials Network, Vancouver, BC, Canada.
Enrico MandarinoCIHR Canadian HIV Trials Network, Vancouver, BC, Canada.
Paul A ShuperInstitute for Mental Health Policy Research and Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON, Canada.
Christian S HendershotDepartment of Psychiatry, University of North Carolina - Chapel Hill, Chapel Hill, NC, USA.
John A CunninghamInstitute for Mental Health Policy Research and Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON, Canada.
Gordon ArbessUnity Health Toronto, St. Michael's Hospital, Toronto, ON, Canada.
Joel SingerCIHR Canadian HIV Trials Network, Vancouver, BC, Canada.
Jeffrey D WardellDepartment of Psychology, York University, 277 Behavioural Sciences Building, 4700 Keele St., Toronto, ON, Canada. jwardell@yorku.ca.ORCID http://orcid.org/0000-0001-9792-280X

Funding

Canadian HIV Trials Network, Canadian Institutes of Health Research CTNPT037CIHR 159754
6 · The paper itself

Abstract

backgroundMany people living with HIV (PLWH) use cannabis for medicinal reasons. Patients' knowledge of the tetrahydrocannabinol (THC) and cannabidiol (CBD) concentrations of the cannabis products they use may be important in helping patients achieve symptom relief while guarding against potential risks of cannabis use. However, no studies have examined cannabinoid concentration knowledge among PLWH.

methodPLWH (N = 29; 76% men, mean age 47 years) reporting cannabis use for both medicinal and nonmedicinal reasons completed daily surveys over 14 days assessing cannabis products used, knowledge of cannabinoid concentrations of cannabis products used, cannabis use motives (medicinal, nonmedicinal, both), and positive and negative cannabis-related consequences. Across the 361 cannabis use days captured on the daily surveys, at least some knowledge of cannabinoid concentrations was reported on an average of 43.1% (for THC) and 26.6% (for CBD) of the days.

resultsGeneralized linear mixed models revealed that participants were more likely to report knowing THC and CBD concentrations on days when they used non-flower forms of cannabis relative to days when they used cannabis flower only. Participants who used cannabis for medicinal reasons on a greater proportion of days had greater knowledge of cannabinoid concentration overall across days. Further, greater overall knowledge of cannabinoid concentrations was associated with fewer reported negative cannabis-related consequences.

conclusionsFindings suggest that among PLWH, knowledge of cannabinoid concentrations may be higher when using non-flower cannabis products and among those reporting primarily medicinal cannabis use. Moreover, knowledge of cannabinoid concentration may protect against negative cannabis-related consequences in this population.

Indexed as

CannabidiolCannabinoidsDronabinolHealth Knowledge, Attitudes, PracticeHIV InfectionsMedical MarijuanaAdultCannabisFemaleHumansMaleMiddle AgedCannabidiolCannabinoidsDronabinolMedical MarijuanaAIDSCannabidiolDelta-9 tetrahydrocannabinolEcological momentary assessmentMarijuanaMedical cannabis

Identifiers

PMID37794278

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.